Literature DB >> 31884679

Increased ferritin levels in non-transfusion-dependent β°-thalassaemia/HbE are associated with reduced CXCR2 expression and neutrophil migration.

Chayada Thiengtavor1,2, Sirikwan Siriworadetkun1,3, Kittiphong Paiboonsukwong3, Suthat Fucharoen3, Kovit Pattanapanyasat4, Jim Vadolas5,6, Saovaros Svasti3,7, Pornthip Chaichompoo1.   

Abstract

Severe bacterial infection is a major complication causing morbidity and mortality in β-thalassaemia/HbE patients. Innate immunity constitutes the first line of defence against bacterial infection. This study aimed to comprehensively investigate the innate immune phenotype and function related to factors predisposing to infection in non-transfusion-dependent (NTD) β°-thalassaemia/HbE patients. Twenty-six patients and 17 healthy subjects were recruited to determine complement activity (C3, C4, mannose-binding lectin and CH50) and surface receptor expression including markers of phagocytosis (CD11b, CD16 and C3bR), inflammation (C5aR) and migration (CD11b, CXCR1 and CXCR2) on neutrophils and monocytes. In addition, phagocytosis and oxidative burst activity of neutrophils and monocytes against Escherichia coli and neutrophil migration were examined. Decreased C3 and surface expression of CD11b and C3bR on neutrophils were found in patients. However, phagocytosis of neutrophils in patients was still in the normal range. Interestingly, patients displayed a significant reduction of surface expression of CXCR2 [1705 ± 217 mean fluorescent intensity (MFI)] on neutrophils, leading to impaired neutrophil migration (9·2 ± 7·7%) when compared to neutrophils from healthy subjects (2261 ± 627 MFI and 27·8 ± 9% respectively). Moreover, surface expression of CXCR2 on neutrophils was associated with splenectomy status, serum ferritin and haemoglobin levels. Therefore, impaired neutrophil migration could contribute to the increased susceptibility to infection seen in NTD β°-thalassaemia/HbE patients.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  bacterial infection; innate immunity; iron overload; β-thalassaemia/HbE

Mesh:

Substances:

Year:  2019        PMID: 31884679     DOI: 10.1111/bjh.16295

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

1.  Extracellular vesicles from thalassemia patients carry iron-containing ferritin and hemichrome that promote cardiac cell proliferation.

Authors:  Anyapat Atipimonpat; Panjaree Siwaponanan; Archrob Khuhapinant; Saovaros Svasti; Kasama Sukapirom; Ladawan Khowawisetsut; Kovit Pattanapanyasat
Journal:  Ann Hematol       Date:  2021-06-21       Impact factor: 3.673

2.  Higher Hospitalization Rate for Lower Airway Infection in Transfusion-Naïve Thalassemia Children.

Authors:  Ti-An Tsai; Chang-Ku Tsai; Yao-Hsu Yang; Zon-Min Lee; Jiunn-Ming Sheen; Yi-Chen Lee; Chih-Min Tsai; Chih-Cheng Chen; Chih-Hao Chang; Chen-Kuang Niu; Hong-Ren Yu
Journal:  Front Pediatr       Date:  2020-11-24       Impact factor: 3.418

3.  Impaired neutrophil extracellular trap formation in β-thalassaemia/HbE.

Authors:  Rattanawan Thubthed; Sirikwan Siriworadetkun; Kittiphong Paiboonsukwong; Suthat Fucharoen; Kovit Pattanapanyasat; Jim Vadolas; Saovaros Svasti; Pornthip Chaichompoo
Journal:  Sci Rep       Date:  2022-02-04       Impact factor: 4.379

4.  Increased non-typhoidal Salmonella hospitalizations in transfusion-naïve thalassemia children: a nationwide population-based cohort study.

Authors:  Jiunn-Ming Sheen; Fang-Ju Lin; Yao-Hsu Yang; Kuang-Che Kuo
Journal:  Pediatr Res       Date:  2021-06-19       Impact factor: 3.953

5.  SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.

Authors:  Ute Schaeper; George Grigoriadis; Jim Vadolas; Garrett Z Ng; Kai Kysenius; Peter J Crouch; Sibylle Dames; Mona Eisermann; Tiwaporn Nualkaew; Shahla Vilcassim
Journal:  Br J Haematol       Date:  2021-05-04       Impact factor: 6.998

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.